Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice

Everolimus is an allosteric inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) widely known for its potent autophagy stimulating properties. Because everolimus shows poor solubility and stability in aqueous solutions, long‐term in vivo administration in preclinical models is challenging. The aim of the present study was to evaluate the effects of short‐term and long‐term everolimus administration on mTORC1 inhibition and autophagy induction in mice.

[1]  F. Locatelli,et al.  Acute Lymphoblastic Leukemia in Children and Adolescents , 2018, The EBMT Handbook.

[2]  Timothy M. Errington,et al.  Replication Study: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2018, eLife.

[3]  G. D. De Meyer,et al.  Potential therapeutic effects of mTOR inhibition in atherosclerosis. , 2016, British journal of clinical pharmacology.

[4]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes , 2015, British journal of pharmacology.

[5]  M. Foti,et al.  Cellular and molecular effects of the mTOR inhibitor everolimus. , 2015, Clinical science.

[6]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[7]  O. Delpuech,et al.  AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules , 2015, Molecular Cancer Therapeutics.

[8]  David E James,et al.  A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. , 2015, Cell reports.

[9]  John C McGrath,et al.  Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP , 2015, British journal of pharmacology.

[10]  Paul A Insel,et al.  Experimental design and analysis and their reporting: new guidance for publication in BJP , 2015, British journal of pharmacology.

[11]  M. Grootaert,et al.  Autophagy in Vascular Disease , 2015, Circulation research.

[12]  K. Guan,et al.  mTOR: a pharmacologic target for autophagy regulation. , 2015, The Journal of clinical investigation.

[13]  Nikhil Wagle,et al.  Response and acquired resistance to everolimus in anaplastic thyroid cancer. , 2014, The New England journal of medicine.

[14]  G. Scagliotti,et al.  Intermittent everolimus administration for malignant insulinoma , 2014, Endocrinology, diabetes & metabolism case reports.

[15]  G. Mills,et al.  Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors , 2014, Oncotarget.

[16]  B. Sacak,et al.  A novel murine model of hypertrophic scarring using subcutaneous infusion of bleomycin. , 2014, Plastic and reconstructive surgery.

[17]  G. Bartsch,et al.  HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A , 2014, Molecular Cancer.

[18]  C. Cui,et al.  Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma , 2014, BMC Cancer.

[19]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[20]  G. D. De Meyer,et al.  mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. , 2014, Atherosclerosis.

[21]  Chi-Long Chen,et al.  Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling* , 2014, Molecular & Cellular Proteomics.

[22]  Yun Zhang,et al.  Selective Inhibition of PI3K/Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque , 2014, PloS one.

[23]  Y. Ohsumi.  Historical landmarks of autophagy research , 2013, Cell Research.

[24]  N. Mizushima,et al.  Autophagy and human diseases , 2013, Cell Research.

[25]  Philippe P Roux,et al.  Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers , 2013, Current Biology.

[26]  R. Nixon,et al.  The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.

[27]  T. P. Neufeld,et al.  ULK1 induces autophagy by phosphorylating Beclin-1 and activating Vps34 lipid kinase , 2013, Nature Cell Biology.

[28]  B. Miller,et al.  Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[29]  Lan Ye,et al.  Rapalogs and mTOR inhibitors as anti-aging therapeutics. , 2013, The Journal of clinical investigation.

[30]  S. Masuda,et al.  Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. , 2012, European journal of pharmacology.

[31]  G. Bartsch,et al.  Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. , 2012, Cancer letters.

[32]  Edmond Y. W. Chan.  Regulation and function of uncoordinated-51 like kinase proteins. , 2012, Antioxidants & redox signaling.

[33]  Jennifer Martinez,et al.  Macrophage autophagy plays a protective role in advanced atherosclerosis. , 2012, Cell metabolism.

[34]  G. Bartsch,et al.  The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. , 2011, Cancer letters.

[35]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[36]  P. Vandenabeele,et al.  Autophagy: for better or for worse , 2011, Cell Research.

[37]  C. Tournier,et al.  The requirement of uncoordinated 51-like kinase 1 (ULK1) and ULK2 in the regulation of autophagy , 2011, Autophagy.

[38]  M. Salvadori,et al.  Long-term outcome of everolimus treatment in transplant patients , 2011 .

[39]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[40]  J. Carew,et al.  Mechanisms of mTOR inhibitor resistance in cancer therapy , 2011, Targeted Oncology.

[41]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[42]  T. C. Woods.  Regulation of cell migration by mTOR is mediated through changes in p27Kip1 phosphorylation , 2010, Cell cycle.

[43]  T. O'reilly,et al.  Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. , 2010, Translational oncology.

[44]  N. Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[45]  R. Crazzolara,et al.  RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia , 2009, Autophagy.

[46]  D. Sabatini,et al.  Rapamycin inhibits mTORC1, but not completely , 2009, Autophagy.

[47]  She Chen,et al.  ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy* , 2009, Journal of Biological Chemistry.

[48]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[49]  D. Teupser,et al.  Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.

[50]  H. Lane,et al.  Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Rubinsztein,et al.  Potential therapeutic applications of autophagy , 2007, Nature Reviews Drug Discovery.

[52]  G. D. De Meyer,et al.  Selective clearance of macrophages in atherosclerotic plaques by autophagy. , 2007, Journal of the American College of Cardiology.

[53]  P. Fauchald,et al.  Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[55]  H. Lane,et al.  Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells , 2004, Cancer Research.

[56]  M. Matsui,et al.  In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. , 2003, Molecular biology of the cell.

[57]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[58]  S. Yalkowsky,et al.  Solubilization of rapamycin. , 2001, International journal of pharmaceutics.

[59]  A. Lajtha,et al.  Rates of protein synthesis in brain and other organs , 1987, International Journal of Developmental Neuroscience.

[60]  J. Dietschy,et al.  Rates of sterol synthesis and uptake in the major organs of the rat in vivo. , 1981, Journal of lipid research.

[61]  G. D. De Meyer,et al.  Methods to assess autophagy in situ--transmission electron microscopy versus immunohistochemistry. , 2014, Methods in enzymology.